Table 3. Logistic regression analyses for predictive pCR.

	Univariate		Multivariate
	OR (95% CI)	P	OR (95% CI)	P
Age (year)
≥50 versus <50	2.13 (0.61–7.41)	0.237
Tumor size (mm)
≥30 versus <30	0.76 (0.22–2.59)	0.664
Nodal status
positive versus negative	1.31 (0.39–4.47)	0.664
ER status
positive versus negative	0.19 (0.05–0.70)	0.013	0.14 (0.02–0.78)	0.025
PR status
positive versus negative	0.09 (0.02–0.53)	0.007
Ki67 labeling index (%)
≥30 versus <30	1.75 (0.42–7.30)	0.442
Nuclear grade
3 versus 1, 2	1.12 (0.32–3.91)	0.856
Tumor subtype
luminal/HER2 versus HER2	0.39 (0.20–0.77)	0.007
PIK3CA mutational status
mutation versus wild type	0.20 (0.03–1.19)	0.076
PTEN expression
high versus low	5.25 (1.23–22.4)	0.025	0.62 (0.04–9.94)	0.734
INPP4B
high versus low	2.55 (0.48–13.5)	0.271
pAkt expression
high versus low	0.56 (0.12–2.60)	0.459
PIK3CA copy number status
gain versus normal/loss	1.36 (0.22–8.41)	0.738
PI3K pathway activation
ahigh versus normal	0.11 (0.03–0.48)	0.003	0.05 (0.003–0.89)	0.041d
bhigh versus normal	0.32 (0.07–1.41)	0.134
chigh versus normal	0.15 (0.04–0.63)	0.01	0.14 (0.02–1.12)	0.064e

OR; odds ratio, CI; confidence interval, ER; estrogen receptor, PR; progesteron receptor, HER2; human epidermal growth factor 2, PTEN; phosphatase and tensin homolog, INPP4B; inositol polyphosphate 4-phosphatase-II.

^ahigh defined as PIK3CA mutation and/or PTEN low.

^bhigh defined as PTEN low and/or INPP4B low.

^chigh defined as PIK3CA mutation and/or PTEN low and/or INPP4B low.

^d,eThe value was indicated when each variable was included in the model, together with ER status and PTEN expression.